ClinicalTrials.gg
DrugRead study by study

Rucaparib clinical trials

Also written Rubraca, CO-338 and PF 01367338.

studies test it
58
open now
3
in phase 3
7
first study started
2007
ClinicalTrials.gov finds 70 studies for rucaparib. How that becomes 58 hereChecked on ClinicalTrials.gov

Every study that search finds has been read, to see whether and how it gives rucaparib. Its counts are asked again every night. How drug pages count

  1. 70Found by its intervention search · See all 70 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 65 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −1
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 69Give rucaparib to participants
  4. −5Observe patients on it, or give it outside a trial
  5. −6Give it beside what is tested
  6. 58Test it: the count on this site

Get an email when these change. Save the rucaparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 Dec 2016 · RUBRACA · NDA 209115 (FDA, Drugs@FDA)
European Union
23 May 2018 · Rubraca · EMEA/H/C/004272 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Rucaparib
49
Rucaparib camsylate
6
6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
2
8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
2
8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt
2

Brand

Rubraca
21

Development codes

CO-338
18
PF 01367338
6
AG 14699
4
C0-338
2
AG 014447
1
AG-014699
1

Studies by the year they started

58 studies that test it; most in 2019 (15)

Studies that test rucaparib, by start year
YearStudies
20072
20102
20111
20131
20142
20151
20166
20176
201813
201915
20205
20213
20221

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
20
Phase 2
38
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 25 · Other 33

pharmaand GmbH (20) · Bristol-Myers Squibb (3) · Memorial Sloan Kettering Cancer Center (2) · University of Michigan Rogel Cancer Center (2) · Dana-Farber Cancer Institute (1) · Alliance for Clinical Trials in Oncology (1) · Royal Marsden NHS Foundation Trust (1) · Brown University (1)

Often tested with

Tested in the same studies.

Nivolumab (11) · Bevacizumab (6) · Atezolizumab (5) · Capecitabine (2) · Durvalumab (2) · Trastuzumab (2) · Fluorouracil (2) · Docetaxel (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 4 most studied

New when their studies opened, with rucaparib beside them; studies of each.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test rucaparib, phase 3 first.

Studies

Open first, then newest update. How each study uses rucaparib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 58

See all 58 studies that test rucaparib →

Behind its US label · 3 — the studies the FDA label of RUBRACA describes

From the Clinical Studies section of RUBRACA (2026-10), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 24 — no other medicine in its arm

Showing 20 of 24. See all 24 →

Tested with established drugs · 6 — they are given beside it
Tested in a combination · 28 — another drug in the study is under test too

Showing 20 of 28. See all 28 →

Beside a new treatment under test · 5 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with rucaparib: DFP-13318 1 · Pegylated SN-38 Conjugate PLX038 1 · ipatasertib 1 · INCB057643 1

Beside supportive care · 1 — a supportive treatment or test is studied
Observed · 5 — patients on it are followed, or it is given outside a trial

Codes

What other systems call rucaparib · ClinicalTrials.gg INT005325

  • MeSH (NLM) C531549rucaparibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 8237F3U7EHRUCAPARIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1862579Confirmed FDA, Wikidata
  • Wikidata Q7376558rucaparibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C137800RucaparibConfirmed FDA, Wikidata
  • DrugBank DB12332One source Wikidata

Also registered as rucaparib camsylate (UNII 41AX9SJ8KO · RxNorm 1862578) and rucaparib phosphate (UNII H3M9955244).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion